{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:15:36Z","timestamp":1789773336178,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute myeloid leukemia (AML) is a malignancy of the stem cell precursors of the myeloid lineage. DNA methylation is an important DNA modification that regulates gene expression. Investigating AML heterogeneity based on DNA methylation could be clinically informative for improving clinical diagnosis and prognosis. The AML subtypes based on DNA methylation were identified by unsupervised consensus clustering. The association of these subtypes with gene mutation, copy number variations, immune infiltration and clinical features were further explored. Finally, univariate, LASSO and multivariate cox regression analyses were used to identify prognosis-associated genes and construct risk model for AML patients. In addition, we validated this model by using other datasets and explored the involved biological functions and pathways of its related genes. Three CpG island methylator phenotypes (CIMP-H, CIMP-M and CIMP-L) were identified using the 91 differential CpG sites. Overall survival, morphology, macrophages M0 and monocytes were distinct from each other. The most frequently mutated gene in CIMP-L was DNMT3A while which in CIMP-M that was RUNX1. In addition, the TIDE scores, used to predict the response to immune checkpoint inhibitors, were significantly different among CIMPs. The CIMP-associated prognosis risk model (CPM) using 32 key genes had convinced accuracy of prediction to forecast 0.5-year, 1-year, 3-year and 5-year survival rates. Moreover, the risk score-related genes were significantly enriched in pattern specification process, regionalization, embryonic organ morphogenesis and other critical cancer-related biological functions. We systematically and comprehensively analyzed the DNA methylation in AML. The risk model we constructed is an independent predictor of overall survival in AML and could be used as prognostic factor for AML treatment.<\/jats:p>","DOI":"10.1007\/s10238-022-00980-4","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T11:05:09Z","timestamp":1673867109000},"page":"2639-2649","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["DNA methylation-based subtypes of acute myeloid leukemia with distinct prognosis and clinical features"],"prefix":"10.1007","volume":"23","author":[{"given":"Jimo","family":"Jian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyuan","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,16]]},"reference":[{"issue":"12","key":"980_CR1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373(12):1136\u201352.","journal-title":"N Engl J Med"},{"issue":"4","key":"980_CR2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000496097","volume":"141","author":"BJ Bain","year":"2019","unstructured":"Bain BJ, Bene MC. Morphological and Immunophenotypic Clues to the WHO Categories of Acute Myeloid Leukaemia. Acta Haematol. 2019;141(4):232\u201344.","journal-title":"Acta Haematol"},{"key":"980_CR3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.blre.2019.03.007","volume":"36","author":"L Naymagon","year":"2019","unstructured":"Naymagon L, Marcellino B, Mascarenhas J. Eosinophilia in acute myeloid leukemia: overlooked and underexamined. Blood Rev. 2019;36:23\u201331.","journal-title":"Blood Rev"},{"issue":"7","key":"980_CR4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ajh.25484","volume":"94","author":"BC Medeiros","year":"2019","unstructured":"Medeiros BC, et al. Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. Am J Hematol. 2019;94(7):803\u201311.","journal-title":"Am J Hematol"},{"issue":"1","key":"980_CR5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"980_CR6","first-page":"25","volume":"38","author":"YP Wang","year":"2018","unstructured":"Wang YP, Lei QY. Metabolic recoding of epigenetics in cancer. Cancer Commun (Lond). 2018;38(1):25.","journal-title":"Cancer Commun (Lond)"},{"issue":"2","key":"980_CR7","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1152\/japplphysiol.00238.2010","volume":"109","author":"S Gonzalo","year":"2010","unstructured":"Gonzalo S. Epigenetic alterations in aging. J Appl Physiol. 2010;109(2):586\u201397.","journal-title":"J Appl Physiol"},{"issue":"22","key":"980_CR8","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"Cancer Genome Atlas Research","year":"2013","unstructured":"Cancer Genome Atlas Research, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059\u201374.","journal-title":"N Engl J Med"},{"issue":"1","key":"980_CR9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/15592294.2017.1405199","volume":"13","author":"L Palomo","year":"2018","unstructured":"Palomo L, et al. DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features. Epigenetics. 2018;13(1):8\u201318.","journal-title":"Epigenetics"},{"issue":"2","key":"980_CR10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00277-020-04358-y","volume":"100","author":"YH Wang","year":"2021","unstructured":"Wang YH, et al. Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA KIAA0125. Ann Hematol. 2021;100(2):487\u201398.","journal-title":"Ann Hematol"},{"issue":"10","key":"980_CR11","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1182\/blood-2008-02-134411","volume":"112","author":"KH Metzeler","year":"2008","unstructured":"Metzeler KH, et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood. 2008;112(10):4193\u2013201.","journal-title":"Blood"},{"issue":"12","key":"980_CR12","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572\u20133.","journal-title":"Bioinformatics"},{"issue":"43","key":"980_CR13","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"980_CR14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417\u201325.","journal-title":"Cell Syst"},{"issue":"11","key":"980_CR15","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747\u201356.","journal-title":"Genome Res"},{"issue":"4","key":"980_CR16","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel CH, et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.","journal-title":"Genome Biol"},{"issue":"50","key":"980_CR17","doi-asserted-by":"crossref","first-page":"20007","DOI":"10.1073\/pnas.0710052104","volume":"104","author":"R Beroukhim","year":"2007","unstructured":"Beroukhim R, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007;104(50):20007\u201312.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"980_CR18","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ng0506-500","volume":"38","author":"M Reich","year":"2006","unstructured":"Reich M, et al. GenePattern 2.0. Nat Genet. 2006;38(5):500\u20131.","journal-title":"Nat Genet"},{"key":"980_CR19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"issue":"10","key":"980_CR20","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550\u20138.","journal-title":"Nat Med"},{"issue":"12","key":"980_CR21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.","journal-title":"Genome Biol"},{"issue":"2","key":"980_CR22","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders S, Pyl PT, Huber W. HTSeq\u2013a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31(2):166\u20139.","journal-title":"Bioinformatics"},{"issue":"1","key":"980_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"J Friedman","year":"2010","unstructured":"Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1\u201322.","journal-title":"J Stat Softw"},{"issue":"12","key":"980_CR24","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3390\/cancers11121958","volume":"11","author":"P Takam Kamga","year":"2019","unstructured":"Takam Kamga P, et al. Notch signaling molecules as prognostic biomarkers for acute myeloid leukemia. Cancers (Basel). 2019;11(12):1958.","journal-title":"Cancers (Basel)"},{"key":"980_CR25","doi-asserted-by":"crossref","unstructured":"The Gene Ontology, C. The Gene Ontology Resource: 20 years and still going strong. Nucleic Acids Res, 2019;47(D1):D330-D338.","DOI":"10.1093\/nar\/gky1055"},{"issue":"1","key":"980_CR26","first-page":"25","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner M, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium Nat Genet. 2000;25(1):25\u20139.","journal-title":"The Gene Ontology Consortium Nat Genet"},{"issue":"1","key":"980_CR27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27\u201330.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"980_CR28","doi-asserted-by":"crossref","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","volume":"45","author":"M Kanehisa","year":"2017","unstructured":"Kanehisa M, et al. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353\u201361.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"980_CR29","doi-asserted-by":"crossref","first-page":"D590","DOI":"10.1093\/nar\/gky962","volume":"47","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa M, et al. New approach for understanding genome variations in KEGG. Nucleic Acids Res. 2019;47(D1):D590\u20135.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"980_CR30","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28(11):1947\u201351.","journal-title":"Protein Sci"},{"issue":"5","key":"980_CR31","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137.","journal-title":"OMICS"},{"issue":"5","key":"980_CR32","first-page":"5823","volume":"16","author":"DS Kim","year":"2018","unstructured":"Kim DS, Lee WK, Park JY. Promoter methylation of Wrap53alpha, an antisense transcript of p53, is associated with the poor prognosis of patients with non-small cell lung cancer. Oncol Lett. 2018;16(5):5823\u20138.","journal-title":"Oncol Lett"},{"issue":"1","key":"980_CR33","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13046-018-0924-y","volume":"37","author":"Y Li","year":"2018","unstructured":"Li Y, et al. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis. J Exp Clin Cancer Res. 2018;37(1):276.","journal-title":"J Exp Clin Cancer Res"},{"issue":"28","key":"980_CR34","doi-asserted-by":"crossref","first-page":"7414","DOI":"10.1073\/pnas.1703577114","volume":"114","author":"X Hao","year":"2017","unstructured":"Hao X, et al. DNA methylation markers for diagnosis and prognosis of common cancers. Proc Natl Acad Sci USA. 2017;114(28):7414\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"980_CR35","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41417-019-0142-6","volume":"27","author":"H Ma","year":"2020","unstructured":"Ma H, et al. Specific glioblastoma multiforme prognostic-subtype distinctions based on DNA methylation patterns. Cancer Gene Ther. 2020;27(9):702\u201314.","journal-title":"Cancer Gene Ther"},{"issue":"11","key":"980_CR36","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41568-019-0196-7","volume":"19","author":"JH Bushweller","year":"2019","unstructured":"Bushweller JH. Targeting transcription factors in cancer - from undruggable to reality. Nat Rev Cancer. 2019;19(11):611\u201324.","journal-title":"Nat Rev Cancer"},{"key":"980_CR37","doi-asserted-by":"crossref","first-page":"14273","DOI":"10.1038\/srep14273","volume":"5","author":"A Yuan","year":"2015","unstructured":"Yuan A, et al. Opposite effects of M1 and M2 macrophage subtypes on lung cancer progression. Sci Rep. 2015;5:14273.","journal-title":"Sci Rep"},{"key":"980_CR38","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3389\/fonc.2020.01399","volume":"10","author":"M Kiss","year":"2020","unstructured":"Kiss M, et al. Systemic reprogramming of monocytes in cancer. Front Oncol. 2020;10:1399.","journal-title":"Front Oncol"},{"key":"980_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat1500","author":"S Singhal","year":"2019","unstructured":"Singhal S, et al. Human tumor-associated monocytes\/macrophages and their regulation of T cell responses in early-stage lung cancer. Sci Transl Med. 2019. https:\/\/doi.org\/10.1126\/scitranslmed.aat1500.","journal-title":"Sci Transl Med"},{"issue":"25","key":"980_CR40","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","volume":"363","author":"TJ Ley","year":"2010","unstructured":"Ley TJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424\u201333.","journal-title":"N Engl J Med"},{"issue":"2","key":"980_CR41","first-page":"325","volume":"19","author":"M Jalili","year":"2018","unstructured":"Jalili M, et al. Prognostic value of RUNX1 mutations in AML: a meta-analysis. Asian Pac J Cancer Prev. 2018;19(2):325\u20139.","journal-title":"Asian Pac J Cancer Prev"},{"key":"980_CR42","doi-asserted-by":"crossref","first-page":"117727191984645","DOI":"10.1177\/1177271919846454","volume":"14","author":"KK Wong","year":"2019","unstructured":"Wong KK, Lawrie CH, Green TM. Oncogenic roles and inhibitors of DNMT1, DNMT3A, and DNMT3B in acute myeloid leukaemia. Biomark Insights. 2019;14:1177271919846454.","journal-title":"Biomark Insights"},{"issue":"1","key":"980_CR43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.2018893982","volume":"134","author":"CP Mill","year":"2019","unstructured":"Mill CP, et al. RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood. 2019;134(1):59\u201373.","journal-title":"Blood"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-022-00980-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-022-00980-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-022-00980-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T17:09:33Z","timestamp":1696093773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-022-00980-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,16]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["980"],"URL":"https:\/\/doi.org\/10.1007\/s10238-022-00980-4","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,16]]},"assertion":[{"value":"10 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}